Rocuronium

Rocuronium Bromide Injection is indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium Bromide Injection is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Rocuronium Bromide Injection is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium.

Rocuronium Bromide Injection is for intravenous use only. Rocuronium Bromide Injection should only be administered by experienced clinicians or trained individuals supervised by an experienced clinician familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents. Individualize the dose for each patient. Peripheral nerve stimulator recommended for determination of drug response and need for additional doses, and to evaluate recovery. Store Rocuronium Bromide Injection with tamper evidence cap and ferrule intact and in a manner that minimizes the possibility of selecting the wrong product. Tracheal intubation: Recommended initial dose is 0.6 mg/kg. Rapid sequence intubation: 0.6 mg/kg to 1.2 mg/kg. Maintenance doses: Guided by response to prior dose, not administered until recovery is evident.

Rocuronium Bromide Injection is contraindicated in patients known to have hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents. Hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents.

Appropriate Administration and Monitorin g: Use only if facilities for intubation, mechanical ventilation, oxygen therapy, and an antagonist are immediately available. Anaphylaxis: Severe anaphylaxis has been reported. Consider cross-reactivity among neuromuscular blocking agents. Risk of Death due to Medication Errors: Accidental administration can cause death. Need for Adequate Anesthesia: Must be accompanied by adequate anesthesia or sedation. Residual Paralysis: Consider using a reversal agent in cases where residual paralysis is more likely to occur.

In clinical trials, the most common adverse reactions (2%) are transient hypotension and hypertension. The following adverse reactions are described, or described in greater detail, in other sections: Anaphylaxis Residual paralysis Myopathy Increased pulmonary vascular resistance Most common adverse reactions (2%) are transient hypotension and hypertension.

Succinylcholine: Use before succinylcholine has not been studied. Nondepolarizing muscle relaxants: Interactions have been observed. Enhanced Rocuronium Bromide Injection activity possible: Inhalation anesthetics, certain antibiotics, quinidine, magnesium, lithium, local anesthetics, procainamide. Reduced Rocuronium Bromide Injection activity possible: Anticonvulsants.

Rocuronium Bromide Injection should be stored at 20°C to 25°C (68°F to 77°F), Excursion permitted between 15°C and 30°C (59°F and 86°F). DO NOT FREEZE.